Two rabbits immunized with a portion of glutamate receptor (GluR) subunit GluR3 (amino acids 245-457) exhibited seizure-like behaviors, suggesting that antibodies to GluR3 may modulate neuronal excitability. Using whole-cell recording, rabbit GluR3 antisera were tested on cultured fetal mouse cortical neurons. In a subset of kainate-responsive neurons, miniperfusion of antisera and IgG evoked currents that were blocked by CNQX. Immunoreactivity to synthetic peptides prepared to subregions GluR3A (amino acids 245-274) and GluR3B (amino acids 372-395) was present in both rabbit sera. Peptide GluR3B, but not GluR3A, specifically blocked antisera-and IgG-evoked currents. Similar receptor activation and anti-GluR3 reactivity was present in sera from patients with active Rasmussen's encephalitis, an intractable pediatric epilepsy. Thus, antibodies to GluR3 define a region involved in agonist binding and specific receptor activation. These data suggest that antibodies to neuronal receptors can function as agonists and that autoantibodies to GluRs may be highly specific neurotoxicants in some neurological diseases.
Introduction
The excitatory amino acid neu rotransmitter glutamate has been implicated in the pathophysiology of epilepsy and neurodegenerative syndromes Choi, 1988; Olney, 1978) . The glutamate receptor (GluR) family is composed of closely related subunits that combine to form receptors that are selectively activated by agonists N-methyI-D-aspartate (NMDA), kainic acid (KA), or m-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA) . The non-NMDA receptors are defined by at least nine cloned subunits that are grouped according to their relatively high sequence identity and similar pharmacology when expressed in Xenopus oocytes or transfected cells . These subunits include GluR1-4, which compose the AMPNKA subfamily, GluR5-7, which compose the KA family, and KA1 or KA2, which form high affinity KA binding sites when expressed in vitro and combine with members of the GluR5-7 family to form functional GluRs (Herb et al., 1992; Puchalski et al., 1994; Huntley et al., 1993; Siegel et al., 1995) .
In two rabbits immunized with bacterially expressed trpE-fusion proteins containing a portion of the putative N-terminal extracellular domain of GluR3, behavioral characteristics indicative of seizure activity were observed after the rabbits developed high titers of anti-GluR3 antibody. These observations suggested the hypothesis that antibodies directed at a Glu R subu nit directly regulate neuronal excitability by binding to and perhaps modulating GluRs. We therefore have analyzed the antigenic basis and subsequent functional consequences of anti-GluR3 antibody interaction with GluRs. In addition to the immunization-induced rabbit anti-GluR3 antibodies, human autoantibodies to GluR3 receptor subunit proteins were also examined for similarities in activity and specificity. The human anti-GluR3 antibodies were obtained from two previously unreported cases of biopsy-proven active Rasmussen's encephalitis, a progressive and intractable form of pediatric epilepsy .
Using epitope mapping and whole-cell patch-clamp recording techniques on fetal mouse cortical neurons in culture, we demonstrate that both rabbit and human antisera contain antibodies directed to at least two epitopes in the extracellular domain of the GluR subunit GluR3, both rabbit and human anti-GluR3 antisera activate a non-NMDA GluR current in a subset of KA-responsive neurons, and the active component of rabbit and human anti-GluR3 antibodies bind to, and can be blocked by, a synthetic peptide of GluR3. This is the first description of an antibody acting as a CNS receptor agonist. These results indicate that the active epitope region (amino acids 372-395) appears to be important in its function as a GluR agonist binding site. Since antibodies to a unique and defined region of the GluR3 receptor can function as a GluR agonist, this presents evidence for a novel concept of the pathophysiologic mechanism underlying specific neuronal degeneration in neurological diseases.
Results
Reactivity of rabbit sera to GluR3 protein was demonstrated on transfected cells expressing GluR3 protein and on cortical neurons in culture. Rabbit anti-GluR3 serum was used to label human embryonic kidney (HEK 293) cells transfected with GluR1, GluR2, GluR3, GluR4, or GluR6. Only cells transfected with GluR3 were labeled by rabbit serum prepared to GluR3 (data not shown). Comparison of the G luR3 fusion protein sequence that includes amino acids 245-457 with the equivalent region of closely related GluR1 and GluR2 uncovered two regions of notable sequence divergence, amino acids 245-274 (termed peptide GluR3A) and 372-395 (termed peptide GluR3B), respectively ( Figure 1A ). Peptides to these regions were synthetically prepared and analyzed for immunoreactivity with rabbit Glu R3 antiserum using an immobilized peptide enzyme linked immunosorbent assay (ELISA). Both rabbits exhibited immunoreactivity to both peptides, although relative reactivity to GluR3B was greater in rabbit 5209 than in rabbit 5210 (Figure 1 B) . These results demonstrate that at least two peptides with low sequence identity to closely related GluR1 or GluR2 contain epitopes recognized by the GluR3-specific rabbit antiserum.
To examine functional consequences of antibody binding to GluRs, we recorded whole-cell currents from fetal mouse cortical neurons in culture. Sera containing antiGluR3 antibody that had undergone repetitive Amicon filtration (50,000 MW cutoff to remove all glutamate and other small molecules) were diluted into electrophysiology external solution for direct application to neurons. Miniper- or region B (GluR3B). Synthetic peptides were made to underlined sequences of Glu R3. Asterisks denote potential N-linked glycosylation sites.
(B) Proportion of total GluR3-specific immunoreactivity to synthetic peptides GluR3A or GluR3B, respectively, in either rabbit 5209 or 5210, as determined by ELISA.
fusion of either rabbit 5209 or 5210 serum (1:8) to voltageclamped neurons produced rapid and reversible nondesensitizing inward currents in a subset of KA-responsive neurons ( Figure 2A ). All cells responding to antibody responded to KA. Application of the final passage filtrate did not evoke currents (data not shown). The number of positively responding cells and peak amplitudes of currents tended to increase with age of the culture (2-5 weeks). In cells tested also with KA, average evoked whole-cell current in positively responding neurons was 0.48 _ 0.02 nA (mean _+ SEM), with a maximum of 1.6 nA (17 of 38 KA-responsive cells). The results from rabbit 5210 were similar, but amplitudes of evoked currents were about one-half that for rabbit 5209, which was consistent with the relative titer to the GluR3B peptide (see Figure  1B ; see below). Relative amplitudes of antibody-evoked currents were variable among cells when compared with currents evoked by 100 pM KA. Overall, the relative potencies of 1:8 GluR3 serum were less than that for 100 pM KA (9.8% _ 4.4% of 100 pM KA response for rabbit 5209 antiserum; 17 cells). Antibody-evoked currents were dilution dependent, with the relative potencies compared with 1:8 serum dilution being 38% _ 13% at 1:16, 19% -+ 9% at1:32, and5% _+ 4% at1:64 ( Figure 2B ). Similar experiments using control rabbit sera did not evoke currents. At a 1:4 dilution, preimmune serum from a GluR3-immunized rabbit, sera from rabbits immunized with a similar portion of GluR5 (amino acids 233-518), or sera from rabbits immunized with neuronal nicotinic acetylcholine receptor subunit l~2 (nAChRI~2) did not evoke inward currents in 3, 11, and 6 cells, respectively ( Figure 2C ). Sera from the rabbits immunized with GluR5 and nAChRI32 fusion proteins have been previously shown to contain high titers of the appropriate antibodies Flores et al., 1992) . To confirm that an IgG fraction was involved in the evoked current response, IgG from rabbit serum was prepared using protein G-sepharose column chromatography. Purified rabbit 5209 IgG fraction at 1:2 dilution (calculated to be 0.35 p.g/Id) evoked currents of similar amplitude when compared with rabbit 5209 sera at 1:8 dilution. Rabbit 5209 sera with IgG removed (1 x concentration of column flow-through) did not evoke currents ( Figure 3A ). At concentrations producing similar peak current amplitudes, IgG-evoked currents exhibited a different kinetic profile compared with the current responses evoked by rabbit antisera. A series of 2 s applications of the purified IgG fraction resulted in a decrement in peak amplitudes or persistent desensitization of receptors that also recovered slowly and incompletely ( Figure 3B ). This was in contrast to the relatively constant peak current amplitude when a series of serum was applied (compare Figure 2A1 and Figure 3B ). With prolonged application (10-30 s), the IgG fraction response deactivated compared with the constant nondesensitizing response produced by antisera ( Figure  3C ). Prolonged applications of purified IgG resulted in a deactivation of current during the application, and receptor responsiveness to IgG recovered slowly (data not shown).
To test the specificity of GluR3 antibody activity on GluRs, rabbit serum (1:8) was mixed with GluR antagonists. Antibody-evoked currents were reduced to 4% __. 2% of control by 40 p.M 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; for rabbit 5209; 6 cells; Figure 4A rents by CNQX was rapid, reversible, and voltage independent. These findings were consistent with those expected for competitive antagonism of GluR agonists by CNQX. As expected, since no NMDA currents were evoked by glutamate in this paradigm, antibody-evoked currents were not reduced by 10 I~M MK-801 (3 cells; data not shown), an NMDA receptor blocker.
To test the specificity of the antibody-evoked current responses further, 0.5 I~g/l~l of GluR3-specific peptides, denoted GluR3A or GluR3B, were incubated with GluR3 antiserum (1:8) or IgG (0.35 I~g/~l at the 1:2 dilution) for 15 rain at room temperature and then applied to cultured neurons. The mixture containing GluR3B peptide nearly completely blocked both the serum-evoked currents (5.6% _+ 2.2% of control for rabbit 5209; 17 cells; Figure  4B1 ) and purified IgG-evoked currents (3 cells; data not shown). However, the mixture containing GluR3A peptide did not block antibody-evoked currents and thus served as a control for the GluR3B peptide (17 cells for 5209 serum; 3 cells for 5209 IgG). Like CNQX, blockade of antibody-evoked currents by GluR3B peptide was rapid, reversible, and voltage independent. Further specificity was tested by synthesizing two additional peptides that divided GluR3B peptide into essentially two halves, termed GluR3B1 and GluR3B2. Each peptide, either alone or in combination, failed to block the rabbit 5209 serum-evoked currents (4 cells each; Figure 4B2 ). Since rabbit 5209 exhibited greater immunoreactivity to GluR3B than rabbit 5210 and was more active as an agonist, this result, taken together with GluR3B peptide block, indicated that this region of GluR3 is the immunologic target region for the antibody activation of this non-NMDA receptor.
As reported previously, patients with Rasmussen's encephalitis harbor autoantibodies to GluR3, and titers of serum autoantibody correspond with disease severity . Consequently, these patients provide an opportunity to determine whether diseaseassociated human autoantibodies to GluR3 activate GluRs. The sera from two previously unreported patients with active and biopsy-proven Rasmussen's encephalitis (cases RW42 and HP65) were prepared as described for the anti-GluR3 rabbit serum. Both patients exhibited strong immunoreactivity towards human embryonic kidney cells transfected with cDNA encoding GluR3, but not GluR1, GluR2, GluR4, or GluR6 ( Figure 5 ).
To examine the hypothesis that human Rasmussen's encephalitis sera containing GluR3 autoantibodies modulate GluR function, we repeated the above experiments using human serum or IgG. Results were similar for both human sera, and findings are shown for RW42. Human sera that had undergone repetitive Amicon filtration were diluted into electrophysiology recording external solution for direct application to neurons. Miniperfusion of the two human sera onto voltage-clamped neurons produced rapid and reversible inward cationic currents in a subset of neurons similar to rabbit 5209 or 5210 sera (shown for RW42 in Figure 6A ). Application of the final passage filtrate (fourth passage from the 50,000 MW cutoff filter) did not evoke currents, demonstrating that glutamate and other possible small GluR agonists were removed. For the human serum RW42 (1:6 dilution), current responses were observed in 13 of 17 neurons tested. For human serum RW42, average evoked whole-cell currents in positively responding neurons was 0.88 ± 0.31 nA, with a maximum of 1.6 nA at the 1:6 dilution (13 responding cells). The results from the other human serum HP65 were similar, but peak currents were smaller when compared with RW42 at equivalent dilutions. Amplitudes of serumevoked currents were smaller when compared with currents evoked by 100 I~M KA in the same cell. In cells tested with both antibody and KA, those responding to antibody also responded to KA (11 cells), but some cells responded to KA and not to serum (6 cells).
Experiments using direct application of human control sera (1:4-8 dilution) from healthy volunteers (three individuals, 4-8 cells each) did not evoke currents (data not shown). In addition, sera (1:4-8 dilution) from seven cases of confirmed paraneoplastic neurological syndromes (23 total cells) and three cases of neurodegenerative syndromes (15 total cells) did not evoke GluR currents (data not shown). A mixture of Rasmussen's encephalitis patient serum (1:4) and glutamate (100 I~M) did not result in a enhancement of glutamate-evoked currents (8 cells; data not shown), as had been seen previously with anti-GluR5 Rabbit Serum (C) Human serum-evoked currents were blocked by GluR3 receptorspecific peptide to region GluR3B, but not by peptide to region GluR3A.
RE
autoantibodies found in a subset of patients with paraneoplastic neurodegenerative syndromes (Gahring et al., 1995) . To confirm that an IgG fraction was involved in the human sera-evoked current responses, purified IgG fractions from both human sera were prepared using protein G-sepharose column chromatography. Purified IgG fraction from human serum evoked glutamate currents, whereas serum with IgG removed (column flow-through) did not evoke currents ( Figure 6B ). The human IgG current deactivation and desensitization responses were similar to those observed for the rabbits (data not shown).
In testing pharmacologic specificity of human antiGluR3 antibody activity on non-NMDA GluRs, serumevoked currents were reduced to 9.7% _+ 1.7% of control (1:6 dilution) by 40 I~M CNQX (10 cells for both human sera; Figure 6A ). As expected for this recording paradigm, human sera-evoked currents were not reduced by 10 I~M MK-801 (7 cells for both sera; data not shown). Like the rabbit antibody, blockade of human antibody-evoked currents by CNQX was rapid, reversible, and voltage independent. Blockade of human antibody-evoked currents by the competitive antagonist CNQX suggested activity at or near the AMPA/KA agonist binding site.
Similar to the rabbit sera, we tested GluR3 peptide specificity of the human antibody-evoked current responses. Serum (1:6) and 0.5 lig/l~l of peptides GluR3A or GluR3B were incubated together 15 min at room temperature and then applied to cultured neurons. The mixture containing GluR3B peptide reduced the evoked currents from both human sera to 26.1% _+ 2.9% of control (12 cells for both sera; Figure 6C ). Like for the rabbits, the mixture containing GluR3A peptide did not block antibody-evoked currents.
Discussion
These studies demonstrate that antisera and purified IgG antibodies to GluR3 directly activate a subpopulation of GluRs. Activation of a subset of kainate-responsive neurons by the GluR3-specific antibody provides further evidence for AMPA/KA receptor diversity and potentially indicates the relative abundance of functional GluR3-containing receptors in different neurons. As an agonist ligand, the activation and relaxation kinetics of the GluR3 antibody also were relatively rapid, suggesting that antibody association and dissociation with the receptor were relatively rapid. The receptor activation was blocked by the competitive antagonist CNQX, thus indicating that the antibody epitope interacted with the AMPA/KA binding or an agonist binding site of the receptor. Blockade of antibody activity by CNQX also suggests that the antibody activation of the receptor was not due nonspecific interactions with the receptor channel protein. The finding that the GluR3B peptide (amino acids 372-395) interferes with antibody activation of GluRs lends further support to the hypothesis that this antibody functions as a highly selective GluR agonist. Furthermore, this peptide region of GluR3 may function in agonist ligand binding and confer ligand-specific pharmacology to a receptor subclass of GluRs. However, this region may not be the specific glutamate binding site because of its sequence diversity in the GluR family, but rather may contribute somehow in the binding of specific ligands and subsequent activation of the receptor. Mutations of amino acid residues in a region just distal to the GluR3B region have been identified to alter ECso values for glutamate agonists acting at the mouse al (GluR1) subunit (Uchino et al., 1992) . Alterations in agonist potency also were found using chimeric reconstructions of regions in rat GluR subunits just distal to the GluR3B region (Stern-Bach et al., 1994) . These findings lend further support to the importance of this vicinity of the receptor sequence as a putative agonist binding site.
Interestingly, the IgG-and serum-evoked currents were observed to have different deactivation and desensitization characteristics. The different GluR kinetic responses observed for IgG versus antisera are reminiscent of the differences in kinetics observed for currents evoked by AMPA (rapidly desensitizing) versus KA (nondesensitizing) when either is applied to the same receptor. The etiology of this difference in kinetics is presently unclear, and its detailed study requires more rapid ligand delivery, owing to the rapidly desensitizing response. The observed differences in kinetics may be due to an undetermined cofactor in the sera, alterations to the antibody during the preparation, or loss of different clones of antibody during the IgG purification process. A cofactor lost in the IgG purification may act differently on these receptors, similar to the interesting effects of cyclothiazide in AMPA receptors (Patneau et al., 1993; Partin et al., 1994) . However, application of the IgG column flow-through with the purified IgG fraction to two neurons did not grossly alter the desensitizing IgG current response kinetics. Although it is possible that the igG was altered physically during its purification, the IgG fraction still activated currents that were blocked by GluR3B.
Other regions of GluRs have been demonstrated to be important in agonist activity. Alterations in GluR agonist potency and pharmacology have been demonstrated to occur from two alternatively spliced versions of subunits GluR1-4, termed flip and flop (Sommer et al., 1990; Partin et al., 1994) . This alternatively spliced sequence occurs considerably further downstream from the GluR3B sequence at a location preceding the fourth transmembrane region of a previously proposed four transmembrane GluR topology model. In this four transmembrane model, the flip/flop region lies intracellularly, but recently proposed three transmembrane models place this region extracellularly (Wo and Oswald, 1994; Hollman et al., 1994) . The observation that the anti-GluR3 antibody was blocked by CNQX suggests that the Glu R3B and flip/flop regions interact in some way to play a role in agonist binding. The tertiary structu re of these two distant regions of the receptor may somehow fold to form one or more binding pockets. Alternatively, these separate regions may be independent agonist binding sites similar to that as proposed for GABAA receptors activated by GABA versus pentobarbital (Amin and Weiss, 1993) . Interestingly, a recently described second site for nuclear RNA editing that occurs immediately preceding the flip/flop sequences of GluR2-4 only affects kinetics of receptor desensitization (Lomeli et al., 1994) . It is possible the GluR3B agonist binding region and the flip/flop and RNA-edited regions interact to regulate activation, deactivation, or desensitization properties. Whether these regions physically interact or act independently remains to be resolved.
The finding that GluR3 antisera activate GluRs indicates that the antibodies could contribute directly to the development of seizure-like activity in the rabbits through binding and activation of the target GluR. Recently, autoantibodies to a specific GluR subunit, GluR3, have been detected in sera of patients with active Rasmussen's encephalitis, a particularly severe form of pediatric epilepsy . Removal of anti-GluR3 antibodies by plasmaphoresis correlated with a reduced frequency of seizures in a case studied. In the present study, the active rabbit and human anti-GluR3 antibodies were demonstrated to have similar physiological properties and antigenic specificity. Activation of GluRs by GluR3 autoantibodies found in Rasmussen's encephalitis as shown here suggests that a pathologic mechanism for seizures and cell loss in these patients is due to GluR excitation and-neuronal excitotoxicity. These findings suggest that an autoimmune process directed at and activating GluRs containing the subunit GluR3 may play a role in the pathophysiological processes of Rasmussen's encephalitis and refractory seizures.
Although direct modulation of the function of a CNS neuronal receptor by antibody has not been reported previously, antibodies are known to act directly upon other receptor systems in human disease. In Grave's disease, antibodies simulate the action of thyroid-stimulating hormone by activating the thyroid-stimulating hormone receptor. Nicotinic acetylcholine receptors at the neuromuscular junction are well-known antibody targets, and in physiologic studies, myasthenic serum has been described to block channels with long open duration (Schuetze et al., 1985) . Similarly, in Lambert-Eaton syndrome, antibodies block calcium channel function (Kim and Neher, 1988) . Although in vivo evidence is lacking, our results suggest that binding of CNS neuronal ion channel receptor antibodies to GluRs may potentially modulate GluR channel function by acting as highly specific agonists, such as in Rasmussen's encephalitis. In the diseases external to the CNS, however, autoantibodies have relatively free access to their target antigen. Our present concept of the CNS blood-brain barrier fails to accommodate the ready passage of all but a minute amount of antibody from the blood to neuronal tissues (Juhler and Neuwelt, 1989) . Therefore, the possibility that focal disruption of the blood-brain barrier, perhaps following trauma or infection, in a region that provides access of autoantibodies to the appropriate epitope on the target receptor would seem feasible. This scenario would account for the focal nature of the immune lesion and would also suggest that in other regions of the brain where the blood brain barrier is intact, particularly the other brain hemisphere, autoantibody fails to gain access to the target antigen and is spared. Consequently, at least three independent events could be hypothesized to initiate and perpetuate the disease state: first, disruption of the blood brain barrier by trauma or possibly infection; second, the presence or ability to produce the GluR3B or related autoantibodies; and third, the presence or display of GluR3 on the neuron in a form that can be accessed by the immune system. A "three-hit" model would also be consistent with the rare incidence of this disease.
Thus, we have shown that antibodies to GluR3 reveal a specific peptide region of the GluR that plays a role in agonist binding and activation of GluRs, as well as confer ligand-specific pharmacology to a Glu R receptor subclass. These data are the first to show that induced antibodies and autoantibodies to a defined region of neuronal receptors function as a receptor agonist. This study also supports the concept that these GluR autoantibodies are candidates for highly specific excitotoxins or neuromodulators. Thus, autoimmunity targeted against a subset of GluR epitopes may be a pathophysiological mechanism for specific neuronal loss in conditions such as epilepsy and neurodegenerative disease syndromes.
Experimental Procedures

Peptide Synthesis
The peptides corresponding to GluR3A (H2N-NNENPMVQQFIQRWV-RLDEREFPEAKNAPY-COOH) or GluR3B (H2N-NEYERFVPFSDQ-QISN DSSSSEN R K-COOH) were synthesized as am ides on a corn mercially available tentagel resin with an Applied Biosystems 430A peptide synthesizer based on the Fmoc Synthesis Protocol including HBTU activation (Kopke et al., 1993) . Peptides were cleaved from the resin with mixtures of trifluoracetic acid and water and pu rifled with reversedphase high pressure liquid chromatography on C18 columns, employing gradients of increasing acetonitril concentrations in an aqueous medium. Peptides were characterized with plasma desorption mass spectroscopy (Bioion 20), and amino acid ana!ysis confirmed the purity and peptide composition. Molecular weights were found to deviate <1% from the expected values. A tyrosine was added to the C-terminus of GluR3A and a lysine to GluR3B to facilitate coupling to a carrier without interfering with the N-terminal sequence. Peptides GluR3B1 (H2N-NEYERFVPFSDQQ-COOH) and GluR3B2 (H2N-SDQQISNDSSSSENRK-COOH) were synthesized in a similar fashion at the University of Utah Peptide Synthesis facility.
GluR Transfection
HEK 293 ceils were transfected transiently with expression plasmids containing either the cDNA for GluR1, GluR2, GluR3, GluR4, or GluR6 by the calcium phosphate method, fixed with 2% paraformaldehyde, and visualized as described Siegel et al., 1995) . Positive controls in all experiments included the rabbit polyclonal antiserum prepared to bacterial fusion proteins expressing a portion of the putative extracellular domain from the respective GluR subunit (Rogers et al., 1991 . The rabbit serum used to identify these subunits are designated as: GluR1, 5011 (El 1); GluR2, 285; GluR3, 5209; GluR4, C74; and GluR5-7, 5211 or 5255. Serum dilutions for immunized rabbits were 1:1000 and 1:500 for human sera. Negative controls included healthy human serum and serum from five patients with paraneoplastic neurodegenerative syndrome (data not shown), which exhibited no immunoreactivity to GluR3. ELISA GluR3A or GluR3B peptide, respectively, was added to Immulon 4 ELISA dishes in 50 ~1 containing 20 ~g/ml peptide and allowed to adsorb overnight at 4°C in a humidified chamber. Peptide was removed, the wells washed with PBS, and the peptide was then blocked for nonspecific protein adsorption with 50 ~1 of PBS supplemented to 3% bovine serum albumin/0.02% Tween 20 (block solution) for 2-4 hr at room temperature or overnight at 4°C. Plates were then washed with PBS/0.02% Tween 20 with an ELISA plate washer, and serum samples from either rabbit 5209 or 5210 diluted from 1:4000 to 1 : 10,000 were added to a subset of wells in PBS. Plates were incubated for 2 hr at room temperature, washed with PBS, and secondary antibody (peroxidase-conjugated anti-rabbit IgG, Jackson Laboratories) diluted to 1:7500 in PBS was added for 1 hr at room temperature. Plates were washed with PBS and developed with 2,2'-azine-bis(3-ethylbenzthioline-6-sulfonic acid) (1 mg/ml in Mcllvaines buffer, 0.1 M sodium phosphate/0.05 M citrate buffer [pH 4.6]) and 0.005% HzO2. Development was monitored at 405 nm on an ELISA reader (Molecular Devices).
Neuronal Cell Culture
Neuronal cultures from fetal (E14-16) mouse cortex were prepared as previously described on poly-L-lysine coated 35 mm Falcon dishes (Skeen et al., 1993) . Cultures were fed every other day using a growth medium consisting of DMEM, 10% horse serum, 30 mM glucose, and 0.5 mM glutamine. Arabinosylcytosine was added for 1 day during the first week in culture to suppress growth of nonneuronal cells.
Electrophysiology
Electrophysiological experiments were performed on 2-5 week old cultures at room temperature. External bath solution consisted of 145 mM NaCI, 1.5 mM KCI, 1 mM CaCI2, 1 mM MgCI2, 10 mM Na-HEPES, and 10 mM glucose (pH 7.4; 320 mOsm adjusted with sucrose). Internal pipette solution consisted of 153 mM CsCI, 10 mM Cs-HEPES, 4 mM MgCI2, and 5 mM EGTA (pH 7.35; -300 mOsm). Solutions were designed for measurement of predominantly sodium inward currents and to block NMDA receptor currents when neurons were voltageclamped at -75 mV. No current was evoked by 100 ~M NMDA with 1 ~M glycine using this paradigm (data not shown). To block other currents, 0.2-1 I~M tetrodotoxin, 10 ~M picrctoxin, and 100 nM strychnine were added to the external solution. External solution was perfused continuously at -2-3 ml/min, and the culture dish maintained a volume of -2 ml. Ligands were applied to cells by 2 s pressure ejection using blunt miniperfusion pipettes (-20 ~m diameter and matched for diameter) about 100 ~m from the cell. Pipettes were kept out of the bath solution until immediately before application and removed from the bath immediately after application. Miniperfusion pipettes were filled and the contents ejected three times with ligand solution to reduce effects of protein binding to glass. Recordings were obtained with an Axon Instruments 200A amplifier using borosilicate glass electrodes (2.5-4 M~). Membrane currents were filtered at 500 Hz and digitized at 2 kHz (Frequency Devices and Axon Instruments Digidata 1200). KA, MK-801, and CNQX were from RBI; TTX, picrotoxin, strychnine, NMDA, glycine, and salts were from Sigma.
For filtration, serum (50 p.I) was diluted 1:9 in external solution buffer used for electrophysiology and added to an Amicon Microcon microconcentrator filter unit 50 (50,000 MW cutoff) and centrifuged at 10,500 rpm in an IEC microfuge until the volume was reduced to less than 100 ~1 (approximately 8 min). This procedure was repeated four times to remove small molecules such as glutamate and transfer larger serum components such as antibody into electrode buffer for application to cells. The final centrifugation was continued until the original serum volume of 50 I~1 was achieved. This volume was defined as 1 x concentration, and dilutions in external recording solution for experiments were made from this concentration. Filtered sera or purified IgG ligands were kept on ice until immediately before use and diluted as 1 part of 1 x concentration to y parts external solution (designated 1 :y dilution). Rabbit and human IgG were purified from whole serum using GammaBind G Sepharose (Pharmacia LKB Biotechnologies) column chromatography according to manufacturers directions. IgG was diluted into external recording solution from this 1 x concentration. Column flow-through was termed serum with IgG removed.
Human Sera
Serum was obtained from two previously unreported cases of pathologically proven Rasmussen's encephalitis. RW42 is a 12-year-old girl diagnosed with active disease by brain biopsy and currently treated with gabapentin. HP65 is an 8-year-old boy diagnosed with active disease by subpial cortical resection and currently treated with phenytoin and valproic acid. The initials used to distinguish these patients reflect randomized codes used for laboratory identification.
